Cytochrome bd promotes Escherichia coli biofilm antibiotic tolerance by regulating accumulation of noxious chemicals.
Alleles
Anti-Bacterial Agents
/ pharmacology
Bacterial Outer Membrane Proteins
/ genetics
Biofilms
/ drug effects
Cytochrome b Group
/ genetics
Dose-Response Relationship, Drug
Drug Resistance, Bacterial
Electron Transport Chain Complex Proteins
/ genetics
Escherichia coli Proteins
/ genetics
Gene Knockdown Techniques
Microbial Sensitivity Tests
Oxidoreductases
/ genetics
Plankton
/ drug effects
Uropathogenic Escherichia coli
/ drug effects
Journal
NPJ biofilms and microbiomes
ISSN: 2055-5008
Titre abrégé: NPJ Biofilms Microbiomes
Pays: United States
ID NLM: 101666944
Informations de publication
Date de publication:
16 04 2021
16 04 2021
Historique:
received:
16
11
2020
accepted:
16
03
2021
entrez:
17
4
2021
pubmed:
18
4
2021
medline:
11
8
2021
Statut:
epublish
Résumé
Nutrient gradients in biofilms cause bacteria to organize into metabolically versatile communities capable of withstanding threats from external agents including bacteriophages, phagocytes, and antibiotics. We previously determined that oxygen availability spatially organizes respiration in uropathogenic Escherichia coli biofilms, and that the high-affinity respiratory quinol oxidase cytochrome bd is necessary for extracellular matrix production and biofilm development. In this study we investigate the physiologic consequences of cytochrome bd deficiency in biofilms and determine that loss of cytochrome bd induces a biofilm-specific increase in expression of general diffusion porins, leading to elevated outer membrane permeability. In addition, loss of cytochrome bd impedes the proton mediated efflux of noxious chemicals by diminishing respiratory flux. As a result, loss of cytochrome bd enhances cellular accumulation of noxious chemicals and increases biofilm susceptibility to antibiotics. These results identify an undescribed link between E. coli biofilm respiration and stress tolerance, while suggesting the possibility of inhibiting cytochrome bd as an antibiofilm therapeutic approach.
Identifiants
pubmed: 33863914
doi: 10.1038/s41522-021-00210-x
pii: 10.1038/s41522-021-00210-x
pmc: PMC8052454
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Outer Membrane Proteins
0
Cytochrome b Group
0
Electron Transport Chain Complex Proteins
0
Escherichia coli Proteins
0
Oxidoreductases
EC 1.-
cytochrome bd terminal oxidase complex, E coli
EC 1.9.3.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Subventions
Organisme : NIAID NIH HHS
ID : F30 AI150077
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007347
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI107052
Pays : United States
Organisme : NIDDK NIH HHS
ID : P20 DK123967
Pays : United States
Références
Kostakioti, M., Hadjifrangiskou, M. & Hultgren, S. J. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb. Perspect. Med. 3, a010306 (2013).
pubmed: 23545571
pmcid: 3683961
doi: 10.1101/cshperspect.a010306
Flemming, H. C. et al. Biofilms: an emergent form of bacterial life. Nat. Rev. Microbiol. 14, 563–575 (2016).
pubmed: 27510863
doi: 10.1038/nrmicro.2016.94
Stewart, P. S. & Franklin, M. J. Physiological heterogeneity in biofilms. Nat. Rev. Microbiol. 6, 199–210 (2008).
pubmed: 18264116
doi: 10.1038/nrmicro1838
Hall-Stoodley, L., Costerton, J. W. & Stoodley, P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2, 95–108 (2004).
pubmed: 15040259
doi: 10.1038/nrmicro821
Donlan, R. M. & Costerton, J. W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167–193 (2002).
pubmed: 11932229
pmcid: 118068
doi: 10.1128/CMR.15.2.167-193.2002
Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318–1322 (1999).
pubmed: 10334980
doi: 10.1126/science.284.5418.1318
Vidakovic, L., Singh, P. K., Hartmann, R., Nadell, C. D. & Drescher, K. Dynamic biofilm architecture confers individual and collective mechanisms of viral protection. Nat. Microbiol. 3, 26–31 (2018).
pubmed: 29085075
doi: 10.1038/s41564-017-0050-1
Flemming, H. C. & Wuertz, S. Bacteria and archaea on Earth and their abundance in biofilms. Nat. Rev. Microbiol. 17, 247–260 (2019).
pubmed: 30760902
doi: 10.1038/s41579-019-0158-9
Mermel, L. A. et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49, 1–45 (2009).
pubmed: 19489710
doi: 10.1086/599376
Floyd, K. A. et al. Adhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 pili. PLoS Pathog. 11, e1004697 (2015).
pubmed: 25738819
pmcid: 4349694
doi: 10.1371/journal.ppat.1004697
Dragoš, A. et al. Division of labor during biofilm matrix production. Curr. Biol. 28, 1903–1913.e1905 (2018).
pubmed: 29887307
pmcid: 6331042
doi: 10.1016/j.cub.2018.04.046
Nadell, C. D., Drescher, K. & Foster, K. R. Spatial structure, cooperation and competition in biofilms. Nat. Rev. Microbiol. 14, 589–600 (2016).
pubmed: 27452230
doi: 10.1038/nrmicro.2016.84
Klein, R. D. & Hultgren, S. J. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat. Rev. Microbiol. 18, 211–226 (2020).
pubmed: 32071440
pmcid: 7942789
doi: 10.1038/s41579-020-0324-0
Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).
pubmed: 25853778
pmcid: 4457377
doi: 10.1038/nrmicro3432
Foxman, B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 7, 653–660 (2010).
pubmed: 21139641
doi: 10.1038/nrurol.2010.190
Beebout, C. J. et al. Respiratory heterogeneity shapes biofilm formation and host colonization in uropathogenic Escherichia coli. mBio https://doi.org/10.1128/mBio.02400-18 (2019).
Borisov, V & Verkhovsky, M. Oxygen as acceptor. EcoSal Plus 6. https://doi.org/10.1128/ecosalplus.ESP-0012-2015 (2015).
Unden, G. & Bongaerts, J. Alternative respiratory pathways of Escherichia coli: energetics and transcriptional regulation in response to electron acceptors. Biochim. Biophys. Acta 1320, 217–234 (1997).
pubmed: 9230919
doi: 10.1016/S0005-2728(97)00034-0
Alteri, C. J., Smith, S. N. & Mobley, H. L. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog. 5, e1000448 (2009).
pubmed: 19478872
pmcid: 2680622
doi: 10.1371/journal.ppat.1000448
Hadjifrangiskou, M. et al. A central metabolic circuit controlled by QseC in pathogenic Escherichia coli. Mol. Microbiol. 80, 1516–1529 (2011).
pubmed: 21542868
pmcid: 3643513
doi: 10.1111/j.1365-2958.2011.07660.x
Hadjifrangiskou, M. et al. Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. J. Bacteriol. 194, 6195–6205 (2012).
pubmed: 22984258
pmcid: 3486386
doi: 10.1128/JB.01012-12
Floyd, K. A. et al. The UbiI (VisC) aerobic ubiquinone synthase is required for expression of type 1 pili, biofilm formation, and pathogenesis in uropathogenic Escherichia coli. J. Bacteriol. 198, 2662–2672 (2016).
pubmed: 27161114
pmcid: 5019064
doi: 10.1128/JB.00030-16
Eberly, A. R. et al. Biofilm formation by uropathogenic Escherichia coli is favored under oxygen conditions that mimic the bladder environment. Int. J. Mol. Sci. https://doi.org/10.3390/ijms18102077 (2017).
Borisov, V. B., Gennis, R. B., Hemp, J. & Verkhovsky, M. I. The cytochrome bd respiratory oxygen reductases. Biochim. Biophys. Acta 1807, 1398–1413 (2011).
pubmed: 21756872
pmcid: 3171616
doi: 10.1016/j.bbabio.2011.06.016
Cotter, P. A., Melville, S. B., Albrecht, J. A. & Gunsalus, R. P. Aerobic regulation of cytochrome d oxidase (cydAB) operon expression in Escherichia coli: roles of Fnr and ArcA in repression and activation. Mol. Microbiol. 25, 605–615 (1997).
pubmed: 9302022
doi: 10.1046/j.1365-2958.1997.5031860.x
Cotter, P. A. & Gunsalus, R. P. Contribution of the fnr and arcA gene products in coordinate regulation of cytochrome o and d oxidase (cyoABCDE and cydAB) genes in Escherichia coli. FEMS Microbiol. Lett. 70, 31–36 (1992).
pubmed: 1315704
doi: 10.1111/j.1574-6968.1992.tb05179.x
Cotter, P. A., Chepuri, V., Gennis, R. B. & Gunsalus, R. P. Cytochrome o (cyoABCDE) and d (cydAB) oxidase gene expression in Escherichia coli is regulated by oxygen, pH, and the fnr gene product. J. Bacteriol. 172, 6333–6338 (1990).
pubmed: 2172211
pmcid: 526817
doi: 10.1128/jb.172.11.6333-6338.1990
Giuffrè, A., Borisov, V. B., Arese, M., Sarti, P. & Forte, E. Cytochrome bd oxidase and bacterial tolerance to oxidative and nitrosative stress. Biochim. Biophys. Acta 1837, 1178–1187 (2014).
pubmed: 24486503
doi: 10.1016/j.bbabio.2014.01.016
Shepherd, M. et al. The cytochrome bd-I respiratory oxidase augments survival of multidrug-resistant Escherichia coli during infection. Sci. Rep. 6, 35285 (2016).
pubmed: 27767067
pmcid: 5073308
doi: 10.1038/srep35285
Mason, M. G. et al. Cytochrome bd confers nitric oxide resistance to Escherichia coli. Nat. Chem. Biol. 5, 94–96 (2009).
pubmed: 19109594
doi: 10.1038/nchembio.135
Jo, J., Cortez, K. L., Cornell, W. C., Price-Whelan, A. & Dietrich, L. E. An orphan cbb
Stewart, P. S. & Parker, A. E. Measuring antimicrobial efficacy against biofilms: a meta-analysis. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.00020-19 (2019).
O’Toole, G. A. et al. Genetic approaches to study of biofilms. Methods Enzymol. 310, 91–109 (1999).
pubmed: 10547784
doi: 10.1016/S0076-6879(99)10008-9
Kragh, K. N., Alhede, M., Kvich, L. & Bjarnsholt, T. Into the well—a close look at the complex structures of a microtiter biofilm and the crystal violet assay. Biofilm https://doi.org/10.1016/j.bioflm.2019.100006 (2019).
Schiessl, K. T. et al. Phenazine production promotes antibiotic tolerance and metabolic heterogeneity in Pseudomonas aeruginosa biofilms. Nat. Commun. 10, 762 (2019).
pubmed: 30770834
pmcid: 6377615
doi: 10.1038/s41467-019-08733-w
Goneau, L. W. et al. Selective target inactivation rather than global metabolic dormancy causes antibiotic tolerance in uropathogens. Antimicrob. Agents Chemother. 58, 2089–2097 (2014).
pubmed: 24449771
pmcid: 4023725
doi: 10.1128/AAC.02552-13
CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Instititute; (2020).
Gupta, K. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52, e103–e120 (2011).
pubmed: 21292654
doi: 10.1093/cid/ciq257
Mironov, A. et al. CydDC functions as a cytoplasmic cystine reductase to sensitize. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2007817117 (2020).
Vadyvaloo, V. et al. Cell-surface alterations in class IIa bacteriocin-resistant Listeria monocytogenes strains. Microbiology 150, 3025–3033 (2004).
pubmed: 15347760
doi: 10.1099/mic.0.27059-0
McCrate, O. A., Zhou, X., Reichhardt, C. & Cegelski, L. Sum of the parts: composition and architecture of the bacterial extracellular matrix. J. Mol. Biol. 425, 4286–4294 (2013).
pubmed: 23827139
doi: 10.1016/j.jmb.2013.06.022
Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67, 593–656 (2003).
pubmed: 14665678
pmcid: 309051
doi: 10.1128/MMBR.67.4.593-656.2003
Delcour, A. H. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta 1794, 808–816 (2009).
pubmed: 19100346
doi: 10.1016/j.bbapap.2008.11.005
Nikaido, H. & Pagès, J. M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36, 340–363 (2012).
pubmed: 21707670
doi: 10.1111/j.1574-6976.2011.00290.x
Schembri, M. A., Kjaergaard, K. & Klemm, P. Global gene expression in Escherichia coli biofilms. Mol. Microbiol. 48, 253–267 (2003).
pubmed: 12657059
doi: 10.1046/j.1365-2958.2003.03432.x
Bhattacharyya, S., Walker, D. M. & Harshey, R. M. Dead cells release a ‘necrosignal’ that activates antibiotic survival pathways in bacterial swarms. Nat. Commun. 11, 4157 (2020).
pubmed: 32814767
pmcid: 7438516
doi: 10.1038/s41467-020-17709-0
Paixão, L. et al. Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J. Biol. Eng. 3, 18 (2009).
pubmed: 19835592
pmcid: 2774284
doi: 10.1186/1754-1611-3-18
Du, D. et al. Multidrug efflux pumps: structure, function and regulation. Nat. Rev. Microbiol. 16, 523–539 (2018).
pubmed: 30002505
doi: 10.1038/s41579-018-0048-6
Sielaff, H., Duncan, T. M. & Börsch, M. The regulatory subunit ε in Escherichia coli F. Biochim. Biophys. Acta Bioenerg. 1859, 775–788 (2018).
pubmed: 29932911
pmcid: 6114093
doi: 10.1016/j.bbabio.2018.06.013
Pagès, J. M., James, C. E. & Winterhalter, M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 6, 893–903 (2008).
pubmed: 18997824
doi: 10.1038/nrmicro1994
Proctor, R. A. et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4, 295–305 (2006).
pubmed: 16541137
doi: 10.1038/nrmicro1384
Bajeli, S. et al. Terminal respiratory oxidases: a targetables vulnerability of mycobacterial bioenergetics? Front. Cell Infect. Microbiol. 10, 589318 (2020).
pubmed: 33330134
pmcid: 7719681
doi: 10.3389/fcimb.2020.589318
Lee, B. S. et al. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. EMBO Mol. Med. https://doi.org/10.15252/emmm.202013207 (2020).
Conradie, F. et al. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med. 382, 893–902 (2020).
pubmed: 32130813
pmcid: 6955640
doi: 10.1056/NEJMoa1901814
de Jager, V. R. et al. Telacebec (Q203), a New Antituberculosis Agent. N. Engl. J. Med. 382, 1280–1281 (2020).
pubmed: 32212527
doi: 10.1056/NEJMc1913327
Mogi, T. et al. Antibiotics LL-Z1272 identified as novel inhibitors discriminating bacterial and mitochondrial quinol oxidases. Biochim. Biophys. Acta 1787, 129–133 (2009).
pubmed: 19111521
doi: 10.1016/j.bbabio.2008.11.016
Mulvey, M. A., Schilling, J. D. & Hultgren, S. J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69, 4572–4579 (2001).
pubmed: 11402001
pmcid: 98534
doi: 10.1128/IAI.69.7.4572-4579.2001
Murphy, K. C. & Campellone, K. G. Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Mol. Biol. 4, 11 (2003).
pubmed: 14672541
pmcid: 317293
doi: 10.1186/1471-2199-4-11
Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175 (2008).
pubmed: 18274517
doi: 10.1038/nprot.2007.521
Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
pubmed: 11328886
pmcid: 55695
doi: 10.1093/nar/29.9.e45
Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteomics 13, 2513–2526 (2014).
pubmed: 24942700
pmcid: 4159666
doi: 10.1074/mcp.M113.031591
Wieczorek, S. et al. DAPAR & ProStaR: software to perform statistical analyses in quantitative discovery proteomics. Bioinformatics 33, 135–136 (2017).
pubmed: 27605098
doi: 10.1093/bioinformatics/btw580
Keseler, I. M. et al. The EcoCyc database: reflecting new knowledge about Escherichia coli K-12. Nucleic Acids Res. 45, D543–D550 (2017).
pubmed: 27899573
doi: 10.1093/nar/gkw1003
Consortium, U. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506–D515 (2019).
doi: 10.1093/nar/gky1049